Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory GI Acute GvHD: A Retrospective Record Review

Allogeneic hematopoietic cell transplantation (allo-HCT) can be curative in patients with hematological malignancies or benign hematological conditions, but its success is limited by the development of acute and chronic graft-versus-host disease (GvHD) [1,2]. Most commonly, acute GvHD (aGvHD) involves the skin, liver, and gastrointestinal (GI) tract [3,4]. Acute GvHD of Grades II –IV and Grades III–IV have been reported in 39–71% and 14–32% of allo-HCT recipients, respectively, despite standard methods of GvHD prophylaxis [5,6].

Source: Biology of Blood and Marrow Transplantation - November 20, 2018 Category: Hematology Authors: Yngvar Fl øisand, Vladimir Lj Lazarevic, Johan Maertens, Jonas Mattsson, Nirav N. Shah, Pierre Zachée, Aliki Taylor, Mona Akbari, Syed Quadri, Andrejus Parfionovas, YiBin Chen Source Type: research